|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q2 FY2017
As of Jun 30, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Total Current Assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND DEFICIENCY IN STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Convertible notes | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accounts payable - related party | ||||||||||||||||||||
| Unearned revenue | ||||||||||||||||||||
| Accrued wages - related party | ||||||||||||||||||||
| Bridge Loan | ||||||||||||||||||||
| Liabilities of discontinued operations | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Deficiency in Stockholders' equity | ||||||||||||||||||||
| Preferred stock Series A, 635,000 shares issued and outstanding | ||||||||||||||||||||
| Preferred stock Series D, 1,000 shares issued and outstanding | ||||||||||||||||||||
| Preferred Stock, $0.001 par value, 50,000,000 shares authorized | ||||||||||||||||||||
| Common stock, $0.001 par value? 500,000,000 shares authorized? 23,091 shares issued and outstanding | ||||||||||||||||||||
| Stock payable | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Deficiency in stockholders' equity | ||||||||||||||||||||
| Total deficiency in stockholders' equity | ||||||||||||||||||||
| Total liabilities and deficiency in stockholders' equity | ||||||||||||||||||||
| Preferred stock Series A, 635,000 shares issued and outstanding | ||||||||||||||||||||
| Preferred Stock Series A | ||||||||||||||||||||
| Preferred Stock Series B | ||||||||||||||||||||
| Preferred Stock Series C | ||||||||||||||||||||
| Preferred Stock Series D | ||||||||||||||||||||
| Preferred Stock Series A | ||||||||||||||||||||
| Preferred Stock Series B | ||||||||||||||||||||
| Preferred Stock Series D | ||||||||||||||||||||
| Preferred Stock Series C | ||||||||||||||||||||
| Total preferred stock Series A, 635,000 shares issued and outstanding | ||||||||||||||||||||
Loading...